Skip to search formSkip to main contentSkip to account menu

daunoform

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Daunorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2001
Review
2001
Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells.
Recent and new results which support a drug-DNA covalent bonding mechanism for cell toxicity of the clinical antitumor drugs… 
2000
2000
Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs.
Selected ion flow tube-chemical ionization mass spectrometry was used to measure formaldehyde levels in human breast cancer cells… 
1999
1999
Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
The anthracycline, antitumor drugs doxorubicin (DOX), daunorubicin (DAU), and epidoxorubicin (EPI) catalyze production of… 
1999
1999
Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.
Recent data indicate that the clinical anthracycline anti-tumor drugs, doxorubicin (DOX), daunorubicin (DAU), and epidoxorubicin… 
1998
1998
Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
The recent discovery that the formaldehyde conjugates of doxorubicin and daunorubicin, Doxoform and Daunoform, are cytotoxic to… 
Highly Cited
1997
Highly Cited
1997
Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
The recent discovery that the clinically important antitumor drugs doxorubicin and daunorubicin alkylate DNA via catalytic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License